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Abstract 
The aims of this study were to determine whether the occurrence of autoimmune diseases is 
increased in patients with multiple sclerosis (MS) and their families and whether this is 
influenced by the type of MS. We conducted a case–control study using a questionnaire 
design to determine whether the prevalence of 11 autoimmune diseases is increased in 
patients with MS and their first-degree relatives compared to a random population control 
group and their first-degree relatives. We found that the total combined prevalence of the 
11autoimmune diseases was higher in the MS patients than in the controls, with an odds ratio 
of 1.7 (95% confidence interval 0.9–3.2; P= 0.10) increasing to 1.9 (1.0–3.5; P= 0.05) after 
adjusting for age. For persons aged under 60 years, the odds ratio was 2.3 (1.1–4.6). We also 
found that there was a significant increase in the total combined prevalence of the 
autoimmune diseases in the first-degree relatives of MS patients compared to the first-degree 
relatives of the control group (P= 0.003, odds ratio 2.2, confidence interval 1.3–3.7). Patients 
with primary progressive MS did not differ from patients with relapsing–remitting or 
secondary progressive MS in the personal or familial occurrence of autoimmune disease. In 
conclusion, although there were sources of possible bias, this study suggests that individuals 
with MS have a genetic predisposition to autoimmunity in general. 
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Introduction 
 
There is increasing evidence that multiple sclerosis (MS) is an autoimmune disease.1,2 
Bias and colleagues have proposed that autoimmunity is inherited as an autosomal 
dominant trait with secondary genes, including major histocompatibility complex 
genes, determining the specific type of autoimmune disease.3 Numerous case reports 
have documented that MS can occur concurrently with other autoimmune disease 
including autoimmune thyroid disease,4 autoimmune gastritis, 4 Addison’s disease, 4 
rheumatoid arthritis, 4 pemphigus vulgaris,4scleroderma,5,6 primary biliary cirrhosis,7–9 
systemic lupus erythematosus10 and ankylosing spondylitis.11,12 A few studies have 
examined the prevalence of autoimmune diseases in patients with MS. Inflammatory 
bowel disease,13 psoriasis 14 and type 1 diabetes mellitus 15 have been reported to 
occur more frequently in MS patients than in the general population, although one 
study found that rheumatoid arthritis, ankylosing spondylitis, type 1 diabetes mellitus, 
primary hypothyroidism and vitiligo were not increased. 16 No increase in total 
autoimmune diseases was found in studies comparing the prevalences in MS patients 
and the general population.16,17  
 
Three case–control studies have suggested an association between MS and other 
autoimmune diseases by showing an increased occurrence of autoimmune diseases in 
MS cases compared to control groups.18–20 Midgard and colleagues conducted a 
hospital-based interviewer questionnaire study of hospitalised patients and found that 
the total combined prevalence of rheumatoid arthritis, psoriasis and goitre was 
significantly higher in MS patients than in controls with mainly surgical diagnoses, 
although the individual diseases were not.18 Seyfert and colleagues in a prospective 
case–control interview study found significantly increased occurrence of total 
autoimmune diseases in MS patients compared with a control group of unselected 
clinic personnel.19 In a recent case–control study, Karni and Abramsky reported the 
increased occurrence of autoimmune thyroid disease in females with MS.20 It has also 
been reported that the prevalence of elevated antinuclear antibodies and other auto 
antibodies is increased in MS patients compared to controls.16,19,21,22  
 
A familial association of MS with other autoimmune diseases has been reported in 
studies on individual family pedigrees 3,23 but has not been demonstrated in case–
control studies.18,24 Inflammatory bowel disease was found to be increased in the 
families of MS patients compared to population prevalences in two studies.25,26  
 
We have conducted a case–control study using a questionnaire design to compare MS 
patients and the general population. Our study aimed to determine whether 11 specific 
autoimmune diseases individually and as a total are more common in MS patients and 
in their first-degree relatives than in random population controls and their first-degree 
relatives. The study also examined whether the type of MS (relapsing–remitting, 
secondary progressive or primary progressive) influences the personal and familial 
occurrence of other autoimmune diseases. 
 
Methods 
 
The cases comprised patients admitted to the Royal Brisbane Hospital Department of 
Neurology between 1992 and 1997 with a diagnosis of clinically definite or 
laboratory-supported definite MS.27 Of 216 cases identified by the International 
Classification of Diseases selection code 340, 205 had medical records that were able 
to be obtained. Of these, 158 had a diagnosis of clinically definite or laboratory-
supported definite MS from the available documentation in the medical records. The 
type and duration of MS were also determined. One patient from Papua New Guinea 
was not included, leaving 157 cases. The majority of cases were from southeast 
Queensland but 27 had been referred from elsewhere in the state of Queensland and 
three from interstate for investigation. The address used for mailing purposes was the 
latest available from the hospital file.  
 
Controls were selected from persons living in the same street (but not immediate 
neighbours) as the cases. The names and addresses of controls were obtained from the 
1997 desktop marketing system (DtMS) database, an up-to-date telephone-based 
electronic directory. Only residential listings were used. The surname, first initial and 
address of three controls for each case were randomly selected using a search and 
retrieval system. Using the directory, addresses for street residents of 24 cases were 
unable to be found (including the three interstate patients) and fewer than three 
controls were able to be found for 19 cases. As the cases without addresses in the 
sampling frame had a prevalence of autoimmune diseases almost identical to that of 
all the cases, they were retained in the analysis to maximise power. Where two sets of 
initials (persons) were listed at the same telephone number, for half of the group a 
questionnaire was addressed to the household and for the other half of the group the 
questionnaire was sent to the person whose initials were listed second. Questionnaires 
were sent to a total of 362 controls.  
 
All cases and controls were mailed a standard covering letter with only minor 
differences in the wording stating whether they were in the case or control group. The 
letter addressed to members of the control group stated that controls had been 
randomly selected as persons without MS. In the covering letter both groups were 
asked to indicate if they or family members had been definitely diagnosed with a 
disease. A second standard covering letter and questionnaire were mailed 4 weeks 
later to all those who had not responded to the initial questionnaire. The importance of 
a reply was stressed in this letter. All cases and controls received the same 
questionnaire with a reply-paid envelope.  
 
The questionnaire asked for date of birth and gender. We used a list of autoimmune 
diseases, which included diseases used in previous studies of this type or those for 
which case reports have documented concurrence with MS, and which are likely to be 
known to the general population. From this list, respondents indicated personal, 
parental, sibling or offspring occurrence of an autoimmune disease. The autoimmune 
diseases selected were accompanied by alternative descriptions which are listed in 
Table 1.The respondents also indicated if a parent, sibling or offspring had MS. The 
final questionnaire that was used had been tested on unselected hospital patients and 
staff and found to be easily able to be completed in less than 2 minutes.  
 
This study was approved by the Research Ethics Committee of the Royal Brisbane 
Hospital. Participation in the study was voluntary and corroboration of reporting of 
personal or family history of an autoimmune disease was not attempted.  
 
Data collection was performed in 1998 and early 1999. Data were entered into the 
Microsoft Excel package and statistical analysis performed primarily with EPI Info 6. 
Where counts were small, Fisher’s exact test was used, and exact 95% confidence 
intervals were calculated and stratified data were combined by maximum likelihood 
methods.28  
 
Results 
 
Of the 157 questionnaires sent to cases, 13 were returned because of an incorrect 
address and two were returned indicating the person was deceased. Of the remainder, 
117 (82%) were returned completed. Of these 117 cases, 58 had relapsing–remitting 
MS, 41 had secondary progressive MS and 18 had primary progressive MS, as 
defined by Lublin and Reingold. 29 Of these 117 cases, there were 722 first-degree 
relatives comprising 304 siblings, 234 parents and 184 children. From the 362 
questionnaires sent to the control group, 32 were returned because of an incorrect 
address and two were returned indicating the addressed person was deceased. Of the 
remainder, 222 (68%) were returned completed. Of these 222 controls, there were 
1582 first-degree relatives comprising 651 siblings, 444 parents and 487 children.  
 
Table 1. List of autoimmune diseases in questionnaire 
     
 
Table 2. Age distribution 
   
 
Gender  
Of the cases, 83 (71%) were females, as were 133 (60%) of the controls. The 
proportion of females in the case group was significantly higher than in the control 
group (P= 0.04). 
 
Age  
The age distributions of cases and controls are shown in Table 2. Proportionally more 
of the controls were aged 60 years and over (29%) than were the cases (11%) (P= 
0.003). One control did not enter a date of birth correctly.  
 
Autoimmune diseases in cases and controls  
Twenty-four autoimmune diseases were reported in the cases and 29 in the control 
group. Twenty cases and 25 controls indicated personal occurrence of one 
autoimmune disease and two cases and two controls reported personal occurrence of 
two autoimmune diseases. The excess proportion of cases with one or more 
autoimmune diseases (19%) compared to controls (12%) did not quite reach formal 
statistical significance (P= 0.10, odds ratio 1.7, confidence interval 0.9–3.2). The 
occurrence of specific autoimmune diseases is shown in Table 3. There were apparent 
excesses of inflammatory bowel disease, psoriasis and rheumatoid arthritis, in 
particular, among the cases but the small numbers prevent firm comment. 
 
Table 3.  Specific autoimmune diseases in cases and controls 
 
 
Autoimmune diseases in first-degree relatives 
Forty cases (34%) and 43 controls (19%) reported at least one first-degree relative 
with an autoimmune disease (P= 0.003, odds ratio 2.2, confidence interval 1.3–3.7). 
There were a total of 53 autoimmune diseases in the first-degree relatives of the cases 
and 60 in those of the controls. The specific autoimmune diseases occurring in first-
degree relatives are shown in Table 4. Ankylosing spondylitis was the only disease 
that occurred much more frequently in the relatives of the cases; in particular, there 
was no excess of inflammatory bowel disease or psoriasis.  
 
Autoimmune diseases according to gender and age  
Of 83 female cases, 15 (18%) reported personal occurrence of an autoimmune disease 
as did seven of 34 male cases (21%). Seven different autoimmune diseases occurred 
in the male cases and the numbers are too small for meaningful analysis of specific 
autoimmune diseases in MS cases according to gender. Sixteen of the 133 female 
controls (12%) and 11 of the 89 male controls (12%) indicated a personal occurrence 
of an autoimmune disease. The odds ratios for males (1.8) and females (1.6) were 
similar. First-degree relatives were not categorised by gender. The prevalence of 
autoimmune disease in cases was similar at all ages (range 14–22%). This also held 
for controls up to the age of 59 years (mean 10%) but increased substantially in older 
persons (mean 19%). The age-specific odds ratio for autoimmune disease was 2.3 
(95% confidence interval 1.1–4.6) in the persons under 60 years of age but only 0.8 
(0.2–3.7) for older persons. The summary age-adjusted odds ratio was 1.9 (1.0–3.5; 
P= 0.05). 
 
Familial MS  
Nine cases and one control reported a first-degree relative with MS (P= 0.0002, odds 
ratio 18.4, confidence interval 2.3–393). 
 
Type and duration of MS  
The numbers of cases with different types of MS reporting the personal or familial 
occurrence of an autoimmune disease are shown in Table 5. There was no significant 
difference among the three types of MS in the reporting of a personal or familial 
occurrence of autoimmune disease. The influence of the duration of MS was analyzed 
by comparing the occurrence of autoimmune diseases in those with MS for less than 
10 years and those with MS for greater than 10 years. There was no marked difference 
in the occurrence of autoimmune diseases between the two groups.  
 
 Table 4. Specific autoimmune diseases in first-degree relatives 
 
 
 Table 5. Influence of the type of MS on association with autoimmune disease 
 
 
Discussion 
 
The present study has shown that the prevalence of autoimmune diseases other than 
MS is higher in patients with MS and their first-degree relatives than in controls and 
their first-degree relatives. However, these results need to be considered in the light of 
a number of possible errors. In a small study of uncommon diseases, chance is 
obviously possible. Furthermore, errors of measurement and selection may occur. 
Measurement errors may be due to misclassification or to reporting bias. The potential 
for misclassification existed for both groups, with some common diseases possibly 
being mistakenly listed, and less common or difficult-to-diagnose diseases having 
been missed. Such similarly poor measurement for cases and controls will produce 
lower odds ratios than truly exist. Studies of this type are also prone to reporting bias: 
it is possible that cases may have been more likely than controls to report a personal 
or familial occurrence of an autoimmune disease, either from being more likely to 
visit medical services or because they may have been more motivated to discuss the 
questionnaire with relatives or to record an uncertain autoimmune disease. However, 
MS cases with cognitive impairment may have been less likely to report an 
autoimmune disease, and the balance of these countervailing influences on the 
apparent effect (odds ratio) remains speculative.  
 
With regard to selection errors, we believe the cases used in this study reflect the 
general MS population in Australia to a reasonable degree. The cases sampled 
included patients who had been recently diagnosed as having MS (and had required a 
hospital admission for cerebrospinal fluid examination), cases who had been admitted 
for intravenous methylprednisolone therapy for relapses, and cases of advanced MS 
with disabling symptoms. However, it is possible that milder cases of MS were 
underrepresented in our group of MS cases. As we selected only cases with clinically 
definite or laboratory-supported definite MS, the possibility of an incorrect diagnosis 
of MS is unlikely. With regard to selection errors in controls, it is certainly difficult to 
select the optimal control group for a set of cases drawn to a tertiary referral centre, 
but the appropriate principle is to use persons who, if they developed MS, would be 
likely to be referred to our unit. On this basis we chose persons living near the cases 
as being more appropriate than a random sample of the whole community since the 
cases were clearly not a random subset of all Brisbane cases.30 However, the age 
distribution of our control group was different from that of the cases, with a higher 
proportion of controls aged 60 and over, and there was a trend for increased 
occurrence of autoimmune diseases with age in our control group. This may have 
reduced a true positive finding, as indicated by the increase in the odds ratio with age 
adjustment. The even higher odds ratio (2.3) for persons under 60 may be a more 
accurate reflection of the overall association. On the other hand, the prevalence of 
autoimmune diseases is higher in females than males, 31 and the proportion of females 
in our group of MS cases was higher than in our control group. However, in our study 
there was no difference between women and men in the occurrence of autoimmune 
diseases in cases or controls or in the total number of subjects studied.  
 
Our finding of an increase in the total prevalence of autoimmune disease in patients 
with MS is consistent with the findings of two previous studies.18,19 In our study, 
although inflammatory bowel disease was significantly more common in MS patients 
than in controls, the numbers were small and the confidence interval was wide. Rang 
and colleagues also found an increased prevalence of inflammatory bowel disease in 
patients with MS.13 Our study did not find an increased prevalence of other specific 
autoimmune diseases with MS as has been shown in other studies, 13–15,20 but this is 
probably because of the small numbers in our study. Our study found a statistically 
significant doubling of autoimmune disease in the first-degree relatives of MS 
patients compared with the first-degree relatives of the control group. This was not 
shown in the study of Midgard and colleagues, who studied a smaller number of 
autoimmune diseases, 18 or in the study by Souberbielle and colleagues who did not 
provide details of the specific familial autoimmune diseases.24 An increased 
occurrence of inflammatory bowel disease in families of MS patients compared with 
known disease prevalence rates has previously been reported.25, 26 This was not 
demonstrated in the present study, perhaps because of the small numbers. Our study 
found a relative risk of 18 for MS in first-degree relatives which is consistent with the 
findings of large familial MS studies. 32, 33 We found that the occurrence of 
autoimmune diseases in individuals with MS and in their first-degree relatives was 
independent of the type or duration of MS. In particular, patients with primary 
progressive MS did not differ from patients with relapsing-remitting or secondary 
progressive MS in the personal or familial occurrence of autoimmune diseases. Our 
study provides further support for an association between MS and other autoimmune 
diseases. We did not include all the autoimmune diseases that have been associated 
with MS, for example Goodpasture’s disease, 34 myasthenia gravis, 35 uveitis, 36 and 
alopecia areata,19 so it is possible that we have actually underestimated the occurrence 
of autoimmune diseases in MS patients and their families. The increased occurrence 
of autoimmune diseases in patients with MS and in their families suggests that 
individuals with MS may have a genetic predisposition to autoimmunity in general. 
 
 
This project was supported by the Royal Brisbane Hospital and by a Short-Term 
Study Grant from The Royal Australasian College of Physicians. 
 
 
References 
 
1. Martin R, McFarland HF. Immunological aspects of experimental allergic 
encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995; 32:121–182. 
2. Pender MP. Multiple sclerosis. In: Pender MP, McCombe PA (eds).Autoimmune 
neurological disease. Cambridge: Cambridge University Press, 1995; 89–154. 
3. Bias WB, Reveille JD, Beaty TH, Meyers DA, Arnett FC. Evidence that 
autoimmunity in man is a Mendelian dominant trait. Am J Hum Genet 1986; 39: 584–
602. 
4. Baker HWG, Balla JI, Burger HG, Ebeling P, Mackay IR. Multiple sclerosis and 
autoimmune diseases. Aust NZ J Med 1972; 3: 256–260. 
5. Trostle DC, Helfrich D, Medsger TA. Systemic sclerosis (scleroderma) and 
multiple sclerosis. Arthritis Rheum 1986; 29: 124–127. 
6. Jawad SH, Askari A, Ward AB. Case history of a patient with multiple sclerosis 
and scleroderma. Br J Rheumatol 1997; 36: 502–509. 
7. Taub WH, Lederman RJ, Tuthill RJ, Falk GW. Primary biliary cirrhosis in a patient 
with multiple sclerosis. Am J Gastroenterol 1989; 84: 415–417. 
8. Pontecorvo MJ, Levinson JD, Roth JA. A patient with primary biliary cirrhosis and 
multiple sclerosis. Am J Med 1992; 92: 433–436. 
9. Noseworthy JH, Ebers GC. Primary biliary cirrhosis and multiple sclerosis. AmJ 
Gastroenterol 1989; 84: 1584–1585. 
10. Kinnunen E, Muller K, Keto P, Ketonen L, Helve T, Sepponen R. Cerebrospinal 
fluid and MRI findings in three patients with multiple sclerosis and systemic lupus 
erythematosus. Acta Neurol Scand 1993; 87: 356–360. 
11. Khan MA, Kushner I. Ankylosing spondylitis and multiple sclerosis. Arthritis 
Rheum 1979; 22: 784–786. 
12. Whitman GJ, Khan MA. Unusual occurrence of ankylosing spondylitis and 
multiple sclerosis in a black patient. Cleve Clin J Med 1989; 56: 819–822. 
13. Rang EH, Brooke BN, Hermon-Taylor J. Association of ulcerative colitis with 
multiple sclerosis. Lancet 1982; 2: 555. 
14. Cendrowski W. Multiple sclerosis and psoriasis. Wiad Lek 1989; 42: 575–578. 
15. Wertman E, Zilber N, Abramsky O. An association between MS and type 
1diabetes mellitus. J Neurol 1992; 239: 43–45. 
16. De Keyser J. Autoimmunity in multiple sclerosis. Neurology 1988; 38:371–374. 
17. Wynn DR, Rodriguez M, O’Fallon M, Kurland LT. A reappraisal of the 
epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology1990; 
40: 780–786. 
18. Midgard R, Grønning M, Riise T, Kvåle G, Nyland H. Multiple sclerosis and 
chronic inflammatory diseases. Acta Neurol Scand 1996; 93: 322–328. 
19. Seyfert S, Klapps P, Meisel C, Fischer T, Junghan U. Multiple sclerosis and other 
autoimmune diseases. Acta Neurol Scand 1990; 81: 37–42. 
20. Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology 
1999; 53: 883–885. 
21. Barned S, Goodman AD, Mattson DH. Frequency of anti-nuclear antibodies in 
multiple sclerosis. Neurology 1995; 45: 384–385. 
22. Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear 
antibodies in multiple sclerosis. Neurology 1997; 49: 857–861. 
23. McCombe PA, Chalk JB, Pender MP. Familial occurrence of multiple sclerosis 
with thyroid disease and systemic lupus erythematosus. J Neurol Sci 1990; 97:163–
171. 
24. Souberbielle BE, Martin-Mondiere C, O’Brien ME, Carydakis C, Cesaro P, Degos 
JD. A case-control epidemiological study of MS in the Paris area with particular 
reference to past disease history and profession. Acta Neurol Scand1990; 82: 303–
310. 
25. Sadovnick AD, Paty DW, Yannakoulias G. Concurrence of multiple sclerosis and 
inflammatory bowel disease. N Engl J Med 1989; 321: 762–763. 
26. Minuk GY, Lewkonia RM. Possible familial association of multiple sclerosis and 
inflammatory bowel disease. N Engl J Med 1986; 314: 586. 
27. Poser CM, Paty DW, Scheinberg L, et el. New diagnostic criteria for multiple 
sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231. 
28. Martin D, Austin H. An efficient program for computing conditional maximum 
likelihood estimates and exact confidence limits for a common odds ratio. 
Epidemiology 1991; 2: 359–362. 
29.Lublin F, Reingold SC. Defining the clinical course of multiple sclerosis. 
Neurology 1996; 46: 907–911. 
30. Rothman KJ. Modern epidemiology. Boston: Little Brown, 1986. 
31. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated 
population burden of selected autoimmune disease in the United States. Clin Immunol 
Immunopathol 1997; 84: 223–243. 
32. Sadovnick AD, Baird PA, Ward RH. Multiple sclerosis: updated risks for 
relatives. Am J Med Genet 1988; 29: 533–541. 
33. Robertson NP, Fraser M, Deans J, Clayton D and Compston DAS. Age adjusted 
recurrence risks for relatives of patients with multiple sclerosis. Brain1996; 119: 449–
455. 
34. Henderson RD, Saltissi D, Pender MP. Goodpasture’s disease associated with 
multiple sclerosis. Acta Neurol Scand 1998; 98: 134–135. 
35. Somer H, Muller K, Kinnunen E. Myasthenia gravis associated with multiple 
sclerosis. Epidemiological survey and immunological findings. J Neurol Sci1989; 89: 
37–48. 
36. Biousse V, Trichet C, Bloch-Michel E, Roullet E. Multiple sclerosis associated 
with uveitis in two large clinic-based series. Neurology 1999; 52: 179–181. 
 
 
